Do you want to read an article? Please log in or register.
Evaluation of Time to Benefit of Statins for the Primary Prevention of Cardiovascular Events in Adults Aged 50 to 75 Years: A Meta-analysis
Cardiovascular Risk and Diseases
RECOMMENDED
Related content
COMMENTED
Lipid-Lowering Drugs
Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants
Am Heart J.
Yebyo HG, Aschmann HE, Kaufmann M, Puhan MA
doi: 10.1016/j.ahj.2018.12.007.
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
LDL-Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men with Primary Elevations of LDL-Cholesterol Levels of 190 mg/dL or Above: Analyses from the WOSCOPS 5-year Randomised Trial and 20-year Observational Follow-Up
Circulation.
Vallejo-Vaz AJ, Robertson M, Catapano AL, Watts GF, Kastelein JJ, Packard CJ, Ford I, Ray KK
doi: 10.1161/
Lipid-Lowering Drugs
A Long-term Benefit Approach vs Standard Risk-Based Approaches for Statin Eligibility in Primary Prevention
JAMA Cardiol.
Thanassoulis G, Sniderman AD, Pencina MJ
doi: 10.1001/jamacardio.
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials
Eur Heart J.
Koskinas KC, Siontis GCM, Piccolo R, Mavridis D, Räber L, Mach F, Windecker S
doi: 10.1093/eurheartj/ehx566.
Cardiovascular Risk and DiseasesHeart FailureMyocardial InfarctionThrombosis and Stroke
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
Circulation.
Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Fabbrini E, Sun T, Li Q, Desai M, Matthews DR; CANVAS Program Collaborative Group
doi: 10.1161/CIRCULATIONAHA.
RECOMMENDED
Cardiovascular Risk and DiseasesHeart, Artery and Coronary Diseases
Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH Study
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
J Am Heart Assoc
Ambrosy AP, Yang J, Sung SH, Allen AR, Fitzpatrick JK, Rana JS, Wagner J, Philip S, Abrahamson D, Granowitz C, Go AS
doi: 10.1161/JAHA.120.020377
Cardiovascular Risk and DiseasesHeart, Artery and Coronary Diseases
Association of Coronary Artery Calcium Score vs Age With Cardiovascular Risk in Older Adults: An Analysis of Pooled Population-Based Studies
JAMA Cardiol.
Yano Y, O'Donnell CJ, Kuller L, Kavousi M, Erbel R, Ning H, D'Agostino R, Newman AB, Nasir K, Hofman A, Lehmann N, Dhana K, Blankstein R, Hoffmann U, Möhlenkamp S, Massaro JM, Mahabadi AA, Lima JAC, Ikram MA, Jöckel KH, Franco OH, Liu K, Lloyd-Jones D, Greenland P
doi: 10.1001/
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
Comparison of Recommended Eligibility for Primary Prevention Statin Therapy Based on the US Preventive Services Task Force Recommendations vs the ACC/AHA Guidelines
JAMA.
Pagidipati NJ, Navar AM, Mulder H, Sniderman AD, Peterson ED, Pencina MJ
doi: 10.1001/jama.2017.3416.
Cardiovascular Risk and Diseases
Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With vs. Without Diabetes: Results from IMPROVE-IT
Circulation.
Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalan R, Spinar J, Park JG, White JA, Bohula E, Braunwald E; IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators
doi: 10.1161/CIRCULATIONAHA.